Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KDST.TA
- Price
- 2468.00
- Stock movement down
- -99.00 (-3.86%)
- Company name
- Kadimastem Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 10.35B
- Ent value
- 10.36B
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -35.35%
- 1 year return
- 425.11%
- 3 year return
- 0.55%
- 5 year return
- -40.57%
- 10 year return
- -36.69%
Last updated: 2025-04-12
DIVIDENDS
KDST.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.19M |
| EPS (TTM) | - |
| FCF per share (TTM) | -1.75 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | 0.00 |
| Net income (TTM) | 0.00 |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.16M |
| Net receivables | 0.00 |
| Total current assets | 5.79M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 13.01M |
| Total assets | 8.37M |
| Accounts payable | 1.93M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 8.24M |
| Total liabilities | 12.73M |
| Shareholder's equity | -4.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.95M |
| Capital expenditures (TTM) | 117.50K |
| Free cash flow (TTM) | -7.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | 208.05% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2550.00 |
| Daily high | 2576.00 |
| Daily low | 2375.00 |
| Daily Volume | 32K |
| All-time high | 801901.58 |
| 1y analyst estimate | - |
| Beta | 0.47 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KDST.TA | S&P500 | |
| Current price drop from All-time high | -99.69% | -14.41% |
| Highest price drop | -99.94% | -56.47% |
| Date of highest drop | 16 Jun 2024 | 9 Mar 2009 |
| Avg drop from high | -76.14% | -11.07% |
| Avg time to new high | 79 days | 12 days |
| Max time to new high | 2192 days | 1805 days |
COMPANY DETAILS
Marketcap
10.35B
Marketcap category
Large-cap
Description
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Employees
12
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to ...
March 10, 2025
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegene...
February 25, 2025
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous sy...
February 10, 2025
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous sy...
January 31, 2025
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous ...
January 28, 2025
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous sy...
January 16, 2025
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous sy...
January 8, 2025
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex cent...
December 30, 2024
PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innov...
July 18, 2024
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, announces the termination of the preliminary term sheet...
May 28, 2024